News und Analysen
At a 2-Year Low, Is This 8%-Yielding Oil and Gas Stock a Buy?
On Sept. 6, Enbridge (NYSE: ENB) stock fell to its lowest level since January 2021 after announcing the $14 billion acquisition (including debt) of three natural gas utilities from Dominion Energy
Time for Dominion Energy to Tell Investors More About Its Long-Term Plans
I have issues with the corporate review that Dominion Energy (NYSE: D) announced when it reported third-quarter 2022 earnings last year. One problem has gotten increasingly upsetting, as it speaks
Buy or Sell: Enbridge Stock Hits 2-Year Low After Dominion Deal
Canadian pipeline giant, Enbridge (NYSE: ENB), dropped big news on Sept. 5 when it announced the $14 billion acquisition (including debt) of three natural gas utilities from Dominion Energy (NYSE:
This Unstoppable Dividend Stock's $14 Billion Acquisition Will Keep Its High-Yielding Payout Well Fueled
Enbridge (NYSE: ENB) has an unceasing record of paying dividends. The Canadian energy infrastructure behemoth has paid its shareholders dividends for over 68 years and has increased its payment in
Why Enbridge Stock Is Falling Today
Enbridge (NYSE: ENB) is making a big bet on natural gas, and investors are worried that the Canadian energy distribution and production company's planned acquisition could cause it some near-term
Dominion Energy (D) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Dominion Energy (NYSE: D)Q2 2023 Earnings CallAug 04, 2023, 10:00 a.m. ET
Operator
Source Fool.com
Why Old Dominion Freight Line Stock Gained 19% in June
Shares of Old Dominion Freight Line (NASDAQ: ODFL) were moving higher last month after the company benefited from news that rival Yellow could soon declare bankruptcy, putting market share up for
Why I Just Bought This 4% Yielding Dividend King
I added Southern Company (NYSE: SO) and Dominion Energy (NYSE: D) to my portfolio a few years ago. Both are large utilities and, at the time I bought them, each had a historically high yield. I'm
You Can't Control Dividend Cuts, but You Can Control What You Do About Them
Advance Auto Parts (NYSE: AAP) cut its dividend by 80% when it reported first-quarter 2023 earnings. Annaly Capital Management's (NYSE: NLY) dividend has been falling for a decade and was just
This Dividend Stock Is Changing, But It Still Won't Tell Investors How
Dominion Energy (NYSE: D) is one of the largest regulated utilities in the United States. It offers a generous dividend yield of 5.3%, well above the industry average of 3.1%, using the Vanguard
3 Top Stocks That Just Went on Sale
Shares of Walgreens Boots Alliance (NASDAQ: WBA), Bristol Myers Squibb (NYSE: BMY) and Dominion Energy (NYSE: D) all recently saw 52-week lows.
The drops were not without reason. Walgreens, like
Why Shares of Grifols Were Up Tuesday
Shares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released
This Stock Could Be the No. 1 Buy in a Recession
The supply chain is an often-invisible aspect of the American economy. Goods are made all over the country, but they must get from one place to another. Less-than-truckload freight company Old
Dominion Energy (D) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Dominion Energy (NYSE: D)Q1 2023 Earnings CallMay 05, 2023, 10:00 a.m. ET
Operator
Source Fool.com
Why Toronto-Dominion Bank Stock Beat the Market Today
Investors continued to be skittish about bank stocks on Thursday, which was understandable given the continuing turmoil with regional lenders. One member of that group escaped the clutches of the
Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA
Fluidra Proposes a Dividend Distribution of 0.55 Euros Per Share
Fluidra, the global leader in equipment and connected solutions in the pool and wellness sector, agreed at its Board of Directors meeting to propose to the General Shareholders' Meeting a dividend
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement
Fluidra Launches its €20 Million Venture Capital Fund, the First to Specialize in Pool and Wellness Startups
Fluidra, a global leader in connected equipment and solutions for the pool and wellness sector, is launching Fluidra Ventures, a €20 million corporate venture capital fund (CVC) investment to lead
Fluidra Results in Line With Guidance, With Sales of €2,051 and EBITDA of €445 Million
Fluidra, the global leader in equipment and connected solutions in the pool and wellness sector, achieved sales of €2,051 million in 2023, down 14% compared to the prior year period. This was
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug
Almirall’s Nine-month 2023 Results:
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.
Financial highlights (€ rounded million)
9M 2023
9M 2022